Clinical Trials Browser

Phase 2/3 × Withdrawn × Lymphoma, T-Cell, Peripheral × Clear all

NCT04021082 2023-02-21

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

Phase 2/3 Withdrawn

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, T-Cell, Lymphoma, T-Cell, Peripheral